Yazar "Aydın, Esra" için listeleme
-
The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients
Ak, Nazmiye; Tuz, Zeynep; Aydın, Esra; Ferhatoğlu, Ferhat; Sarı, Murat; Paksoy, Nail; Doğan, İzzet; Yıldız, Anıl; Dişçi, Rian; Saip, Pınar Mualla (Scientific and Technical Research Council of Turkey, 2024)Background/aim: The study is aimed to determine the relationship between the delivery and breastfeeding history of the patients and the clinicopathological properties of breast cancer. Materials and methods: A questionnaire ... -
Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas
Okcu, Oğuzhan; Öztürk, Çiğdem; Yalçın, Nazlıcan; Yalçın, Anıl Can; Şen, Bayram; Aydın, Esra; Öztürk, Ahmet Emin (Elsevier, 2024)Introduction: Despite screening, the incidence of breast cancer is increasing worldwide. Neoadjuvant chemotherapy (NAC) response is one of the most important parameters taken into consideration in surgery, optimal adjuvant ... -
Factors affecting mortality in COVID-19 patients treated with tocilizumab
Cüre, Osman; İlkkılıç, Kadir; Şen, Bayram; Arpa, Medeni; Aydın, Esra; Avcı, Uğur; Tüfekçi, Damla; Polat, Hatice Beyazal; Kızılkaya, Bayram (Yuzuncu Yil Universitesi Tip Fakultesi, 2024)The aim of our study was to evaluate the risk factors associated with mortality in COVID-19 patients. During March 2020 to March 2022, 136 patients who were treated with tocilizumab in the service and intensive care unit ... -
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gümüşay, Özge; Bayram, Ertuğrul; Demirel, Burçin Çakan; Acar, Ömer; Aksoy, Sercan; Baytemur, Nazife Köse; Şahin, Elif; Çabuk, Devrim; Başaran, Gül; Paydaş, Semra; Yaren, Arzu; Güven, Deniz Can; Erdoğan, Atike Pınar; Demirci, Umut; Yaşar, Alper; Bayoğlu, İbrahim Vedat; Hızal, Mutlu; Gülbağcı, Mutlu; Paksoy, Nail; Davarcı, Sena Ece; Yılmaz, Funda; Doğan, Özlem; Orhan, Sibel Oyucu; Kayıkcıoğlu, Erkan; Aytaç, Ali; Keskinkılıç, Merve; Moçan, Eda Eylemer; Ünal, Ölçün Ümit; Aydın,Esra; Yücel, Hakan; Işık, Deniz; Eren, Önder; Uluç, Başak Oyan; Özçelik, Melike; Hacıbekiroğlu, İlhan; Aydıner, Adnan; Demir, Hacer; Öksüzoğlu, Berna; Çılbır, Ebru; Çubukçu, Erdem; Çetin, Bülent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yıldırım, Nilgün; Alkan, Ali; Selçukbiricik, Fatih; Aksoy, Asude; Karakaş, Yusuf; Özkanlı, Gülhan; Duman, Berna Bozkurt; Aydın, Dinçer; Dulgar, Özgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tuğba; Aykan, Musa Barış; İnal, Ali; İriağaç, Yakup; Kalkan, Nurhan Önal; Keser, Murat; Sakalar, Teoman; Menekşe, Serkan; Kut, Engin; Bilgin, Burak; Karaoğlanoğlu, Müge; Sunar, Veli; Özdemir, Özlem; Turhal, Nazım Serdar; Karadurmuş, Nuri; Yalçın, Bülent; Şendur, Mehmet Ali Nahit (Future Medicine Ltd, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...